Renal Cell Carcinoma (RCC) Epidemiology Analysis and Forecast to 2033
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Renal Cell Carcinoma (RCC) Report Overview
In the 8MM, there were 199,400 diagnosed incident cases of RCC in 2023. The diagnosed incident cases of RCC will register an AGR of more than 1% during 2023-2033. Renal cell carcinoma (RCC) is a disease in which cancer cells are found in the lining of kidney tubules.
Renal Cell Carcinoma (RCC) Market Outlook, 2023-2033 (Diagnosed Incident Cases)
Buy the Full Report for More Insights into the Renal Cell Carcinoma (RCC) Market Forecast
The renal cell carcinoma (RCC) market research report provides an overview of the risk factors, comorbidities, and global and historical trends for RCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report also includes a 10-year epidemiological forecast for the diagnosed incident cases of RCC and the five-year diagnosed prevalent cases of RCC.
| Market Size (2023) | 199,400 Cases |
| AGR (2023-2033) | >1% |
| Forecast Period | 2023-2033 |
| Key Countries | · The US
· France · Germany · Spain · Italy · The UK · Japan · China |
| Key Sex Segments | · Men
· Women |
| Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Renal Cell Carcinoma (RCC) Market Segmentation by Country
The key countries across the 8MM are the US, France, Germany, Spain, Italy, the UK, Japan, and China. In 2023, the US accounted for the highest number of diagnosed incident cases of RCC in the 8MM. Any change in the total incident cases of RCC is attributable to changing population demographics and changing diagnosed incidence rates based on trend analysis in the 8MM.
Renal Cell Carcinoma (RCC) Market Analysis by Country, 2023 (%)
Buy the Full Report for More Country Insights into the Renal Cell Carcinoma (RCC) Market
Download a Free Report Sample
Renal Cell Carcinoma (RCC) Market Segmentation by Sex
Based on sex, the market can be segmented into men and women. In 2023, the diagnosed incident cases of RCC in the 8MM were higher in men than women. Among the 8MM, Japan had the largest difference in diagnosed incident cases of RCC between men and women.
Renal Cell Carcinoma (RCC) Market Analysis by Sex, 2023 (%)
Buy the Full Report for More Sex Insights into the Renal Cell Carcinoma (RCC) Market
Segments Covered in the Report
Renal Cell Carcinoma (RCC) Country Outlook (Diagnosed Incident Cases)
- The US
- France
- Germany
- Spain
- Italy
- The UK
- Japan
- China
Renal Cell Carcinoma (RCC) Sex Outlook (Diagnosed Incident Cases)
- Men
- Women
Scope
This report provides an overview of the risk factors and comorbidities, and the global and historical epidemiological trends for RCC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). The report includes a 10-year epidemiology forecast for the diagnosed incident cases of RCC and the five-year diagnosed prevalent cases of RCC. The diagnosed incident cases of RCC are segmented by age (18 years and older) and sex (men and women). The diagnosed incident cases of RCC among men and women are segmented by stage at diagnosis (stage I, stage II, stage III, and stage IV), by International mRCC Database Consortium Prognostic Model (IMDC) risk group (favorable, intermediate, and poor risk), by stage IV non-clear cell RCC (nccRCC) patients, by RCC subtype (papillary RCC [pRCC] and chromophobe RCC [chRCC]), and by gene mutations (VHL, BAP1, SETD2, and ARID1A). The five-year diagnosed prevalent cases of RCC are also included in the report. This epidemiology forecast for RCC is supported by data obtained from country-specific oncology databases, peer-reviewed articles, and population-based studies. The forecast methodology was kept consistent across the 8MM to allow for a meaningful comparison of the forecast diagnosed incident and diagnosed prevalent cases of RCC across these markets.
Reasons to Buy
The Renal Cell Carcinoma epidemiology series will allow you to:
Develop business strategies by understanding the trends shaping and driving the global Renal Cell Carcinoma market.
Quantify patient populations in the global Renal Cell Carcinoma market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for Renal Cell Carcinoma therapeutics in each of the markets covered.
Understand magnitude of the Renal Cell Carcinoma population by age, sex, stage at diagnosis, subtypes, and genetic mutations.
Table of Contents
Table
Figures
Frequently asked questions
-
How many diagnosed incident cases of RCC were seen in the 8MM in 2023?
In 2023, there were 199,400 diagnosed incident cases of RCC in the 8MM.
-
What will the growth rate of the RCC market be during the forecast period?
The diagnosed incident cases of RCC will register an AGR of more than 1% during 2023-2033.
-
Which was the leading sex segment in the RCC market in 2023?
In 2023, the number of diagnosed incident cases of RCC was higher in men in the 8MM combined.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Renal Cell Carcinoma reports


